Dr. David E. Moll, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
7777 Hennessy Blvd, Suite 1000
Baton Rouge, LA 70808
Who else practices at this address →
East Baton Rouge Parish includes primary care (46% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 907
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
LA license 203702 -
Cardiovascular Disease Physician
LA license MD.203702 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Our Lady of the Lake Regional Medical Center Baton Rouge, LA
- Ochsner Medical Center - Baton Rouge Baton Rouge, LA
- Baton Rouge General Medical Center Baton Rouge, LA
- Riverland Medical Center Ferriday, LA
Medical groups
- Our Lady of the Lake Physician Group LLC (644 clinicians)
- Baton Rouge General Physicians Inc (191 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 907
- Services billed
- 2,531
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 539 | 339 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 457 | 326 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 287 | 263 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 245 | 235 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 116 | 51 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 64 | 60 |
| New patient office or other outpatient visit, 45-59 minutes | 60 | 60 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 38 | 17 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 17 | 17 |
| Ultrasound of heart blood flow, valves and chambers | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Baton Rouge, LA | 257 |
| Entresto (sacubitril/valsartan) Other prescribers in Baton Rouge, LA | 205 |
| Spironolactone Other prescribers in Baton Rouge, LA | 194 |
| Torsemide Other prescribers in Baton Rouge, LA | 190 |
| Eliquis (apixaban) Other prescribers in Baton Rouge, LA | 104 |
| Atorvastatin Calcium Other prescribers in Baton Rouge, LA | 90 |
| Jardiance (empagliflozin) Other prescribers in Baton Rouge, LA | 73 |
| Amlodipine Besylate Other prescribers in Baton Rouge, LA | 73 |
| Rosuvastatin Calcium Other prescribers in Baton Rouge, LA | 71 |
| Furosemide Other prescribers in Baton Rouge, LA | 66 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 66 payments worth $20,788 in total to this clinician.
| Actelion Pharmaceuticals US, Inc. | $18,533 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $1,462 |
| Pfizer Inc. | $195 |
| Merck Sharp & Dohme LLC | $139 |
| Biotronik Inc. | $65.00 |
| United Therapeutics Corporation | $59.82 |
| Amgen Inc. | $45.39 |
| AstraZeneca Pharmaceuticals LP | $44.33 |
| Compensation for services other than consulting (speaking, faculty) | $16,008 |
|---|---|
| Travel and Lodging | $3,312 |
| Food and Beverage | $1,343 |
| Education | $126 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,940 |
| Actelion Pharmaceuticals US, Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,940 |
| Actelion Pharmaceuticals US, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Actelion Pharmaceuticals US, Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Actelion Pharmaceuticals US, Inc. Feb 4, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Adempas; Kerendia · Cardio-pulmonary | $1,413 |
| Actelion Pharmaceuticals US, Inc. Mar 18, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Mobile, AL · in-kind | $1,086 |
| Actelion Pharmaceuticals US, Inc. Mar 17, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $840 |
| Actelion Pharmaceuticals US, Inc. Apr 18, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Houma, LA · in-kind | $832 |
| Actelion Pharmaceuticals US, Inc. May 23, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Thibodaux, LA · in-kind | $734 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. Nov 12, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $99.99 |
| Bayer HealthCare Pharmaceuticals Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Adempas; Kerendia · Cardio-pulmonary | $1,413 |
| Merck Sharp & Dohme LLC Sep 5, 2025 | Education WINREVAIR · CARDIOVASCULAR · in-kind | $25.70 |
| Actelion Pharmaceuticals US, Inc. Jul 30, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $315 |
| Actelion Pharmaceuticals US, Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Actelion Pharmaceuticals US, Inc. May 23, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Thibodaux, LA · in-kind | $734 |
| Actelion Pharmaceuticals US, Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Actelion Pharmaceuticals US, Inc. May 1, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Hammond, LA · in-kind | $632 |
| Actelion Pharmaceuticals US, Inc. Apr 28, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Hammond, LA · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Apr 28, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Thibodaux, LA · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Apr 21, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,940 |
| Actelion Pharmaceuticals US, Inc. Apr 18, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Houma, LA · in-kind | $832 |
| Actelion Pharmaceuticals US, Inc. Apr 2, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Hammond, LA · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Mar 24, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Houma, LA · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,940 |
| Actelion Pharmaceuticals US, Inc. Mar 18, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Mobile, AL · in-kind | $1,086 |
| Actelion Pharmaceuticals US, Inc. Mar 17, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $840 |
| Actelion Pharmaceuticals US, Inc. Feb 21, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Mobile, AL · in-kind | $5.50 |
| Actelion Pharmaceuticals US, Inc. Feb 4, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $52,950 in research payments for these studies, mostly to the institutions running them.
- Finality Study #22618
Bayer HealthCare Pharmaceuticals Inc. - REDEFINE-HF Study #22438
Bayer HealthCare Pharmaceuticals Inc. - Confirmation Study #22563
Bayer HealthCare Pharmaceuticals Inc. - ISM2502004A--Specimen Collection for the Evaluation of Alere NT-proBNP for Alinity i System in Outpatient Setting for Heart Failure (LANAIS-HF)
Abbott Laboratories
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.